News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Moderna, Inc. reports Q4 revenues of $2.8 billion with a GAAP net income of $217 million. Expects regulatory approvals for RSV vaccine and forecasts 2024 product sales of $4 billion -
COMMUNIQUÉ DE PRESSE
Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
Moderna, Inc.'s CEO Stéphane Bancel elected to National Academy of Engineering for distinguished contributions to engineering and manufacturing of pharmaceutical products, including COVID-19 vaccine. Company has 45 mRNA therapeutic and vaccine programs in pipeline -
COMMUNIQUÉ DE PRESSE
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Moderna, Inc. to report Q4 and full year 2023 financial results and provide corporate update in live conference call and webcast on February 22, 2024. Archived webcast available for one year -
COMMUNIQUÉ DE PRESSE
Moderna Named to Fortune's List of World's Most Admired Companies
Moderna, Inc. has been recognized on Fortune's World's Most Admired Companies list, positioning among the top-50 companies. The company focuses on mRNA medicine for disease prevention and treatment, recognized for innovation and public health impact -
COMMUNIQUÉ DE PRESSE
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Moderna, Inc. (NASDAQ: MRNA) announces impressive financial updates for 2023, with approximately $6.7 billion in product sales and an increased COVID-19 market share in the U.S. The company reiterates the expectation of approximately $4 billion in product sales for 2024, highlighting upcoming late-stage programs with anticipated milestones in 2024 and 2025. The nine late-stage programs include respiratory vaccines, next-generation COVID-19 vaccine, seasonal flu vaccine, combination vaccine against seasonal flu and COVID-19, cytomegalovirus (CMV) vaccine, individualized neoantigen therapy (INT), and rare disease therapeutics. Moderna focuses on returning to sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment. For further details, Jamey Mock will present an update on the Company and its pipeline of mRNA development programs at the 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024, at 3:45 p.m. PT/6:45 p.m. ET. -
COMMUNIQUÉ DE PRESSE
Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
